ClinicalTrials.Veeva

Menu

Effect of Acute Exercise on Cognitive Functions and Blood Markers of Brain Plasticity in Regular Chronic Cannabis Users (CANNABEX)

U

University Hospital, Lille

Status

Enrolling

Conditions

Cannabis User

Treatments

Other: activity test

Study type

Interventional

Funder types

Other

Identifiers

NCT06081218
2016_70

Details and patient eligibility

About

The endocannabinoid system (ECS) is a complex endogenous signaling system made up of transmembrane cannabinoid receptors (CB1 and CB2 receptors), their endogenous lipid-derived ligands (the endocannabinoids - eCBs), and enzymes for ligand biosynthesis and degradation. Interestingly, exercise increase plasma AEA, one of the most famous endocannabinoid. This increase could be involved in exercise-induced neurogenesis and other beneficial exercise adaptations. Chronic cannabis use is associated with alteration of ECS activity. The aim of the study is to compare ECS response to exercise between chronic cannabis users and non-users.

Enrollment

60 estimated patients

Sex

All

Ages

18 to 35 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Cannabis consumer group:

  • Cannabis consumption > 100 times in lifetime, last exposure < 7 days, and recent exposure > 10 times in the month.
  • Positive toxicological urine test for ∆-9-THC.
  • Having a cannabis use disorder according to the CAST.

Healthy group:

  • Negative urine toxicological test for cannabis.
  • No regular cannabis use for more than 6 months once in a lifetime.
  • No cannabis consumption in the 6 months preceding the study.

Exclusion criteria

For all subjects :

  • Disorders of use of other substances (alcohol, cocaine, opioid, or synthetic drugs).
  • Alcohol consumption greater than 30g per day (averaged over one week) and/or alcohol abuse the week preceding the visit.
  • Under medical treatment.
  • Presence of diagnosed neurological disorders.
  • Diagnosis of a psychotic picture entering axis I, DSM-5.
  • Chronic progressive disease or in remission.
  • Body mass index > 30 kg/m2 (i.e. presence of obesity).

Trial design

Primary purpose

Other

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

60 participants in 2 patient groups

Chronic cannabis users
Experimental group
Treatment:
Other: activity test
Healthy subjects
Sham Comparator group
Treatment:
Other: activity test

Trial contacts and locations

1

Loading...

Central trial contact

Olivier Cottencin, MD,PhD; Francois-xavier Gamelin, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems